Mapping of conformational epitopes on human proteinase 3, the autoantigen of Wegener's granulomatosis

Journal of Immunology

Volumn 185, Issue 1, 2010, Pages 387-399

  Kuhl, Angelika ^a,f   Korkmaz, Brice ^a,g   Utecht, Bert ^b   Kniepert, Andrea ^a,c   Schönermarck, Ulf ^d   Specks, Ulrich ^e   Jenne, Dieter E ^a  

^a MAX PLANCK INSTITUTE OF NEUROBIOLOGY   (Germany)

^b Utecht and Lüdemann ^*

^c UNIVERSITY OF KONSTANZ   (Germany)

^d LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^e MAYO CLINIC   (United States)

^f ROCHE DIAGNOSTICS GMBH   (Germany)

^g UNIVERSITÉ DE TOURS   (France)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIGEN; MONOCLONAL ANTIBODY; MYELOBLASTIN; NEUTROPHIL CYTOPLASMIC ANTIBODY; EPITOPE; SERINE PROTEINASE INHIBITOR;

AMINO TERMINAL SEQUENCE; ARTICLE; CARBOXY TERMINAL SEQUENCE; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME ANALYSIS; ENZYME CONFORMATION; HUMAN; PRIORITY JOURNAL; PROTEIN BINDING; STRUCTURE ANALYSIS; WEGENER GRANULOMATOSIS; AMINO ACID SEQUENCE; ANIMAL; ANTIBODY COMBINING SITE; BINDING COMPETITION; CELL LINE; COMPARATIVE STUDY; CROSS REACTION; ENZYMOLOGY; HAPLORHINI; IMMUNOLOGY; MACACA; METABOLISM; METHODOLOGY; MOLECULAR GENETICS; MOUSE; PAN TROGLODYTES; PEPTIDE MAPPING; PROTEIN CONFORMATION;

AMINO ACID SEQUENCE; ANIMALS; ANTIBODIES, MONOCLONAL; AUTOANTIGENS; BINDING SITES, ANTIBODY; BINDING, COMPETITIVE; CELL LINE; CROSS REACTIONS; EPITOPES; HUMANS; HYLOBATES; MACACA MULATTA; MICE; MOLECULAR SEQUENCE DATA; MYELOBLASTIN; PAN TROGLODYTES; PEPTIDE MAPPING; PROTEIN CONFORMATION; SERINE PROTEINASE INHIBITORS; WEGENER GRANULOMATOSIS;

EID: 77956195339     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.0903887     Document Type: Article

References (44)

1. Kallenberg, C. G., P. Heeringa, and C. A. Stegeman. 2006. Mechanisms of Disease: pathogenesis and treatment of ANCA-associated vasculitides. Nat. Clin. Pract. Rheumatol. 2: 661-670.
2. Müller, A., J. Voswinkel, S. Gottschlich, and E. Csernok. 2007. Human proteinase 3 (PR3) and its binding molecules: implications for inflammatory and PR3-related autoimmune responses. Ann. N.Y. Acad. Sci. 1109: 84-92.
3. Rarok, A. A., P. C. Limburg, and C. G. Kallenberg. 2003. Neutrophil-activating potential of antineutrophil cytoplasm autoantibodies. J. Leukoc. Biol. 74: 3-15.
4. Specks, U. 2000. What you should know about PR3-ANCA. Conformational requirements of proteinase 3 (PR3) for enzymatic activity and recognition by PR3-ANCA. Arthritis Res. 2: 263-267.
5. Bauer, S., M. Abdgawad, L. Gunnarsson, M. Segelmark, H. Tapper, and T. Hellmark. 2007. Proteinase 3 and CD177 are expressed on the plasma membrane of the same subset of neutrophils. J. Leukoc. Biol. 81: 458-464.
6. von Vietinghoff, S., G. Tunnemann, C. Eulenberg, M. Wellner, M. Cristina Cardoso, F. C. Luft, and R. Kettritz. 2007. NB1 mediates surface expression of the ANCA antigen proteinase 3 on human neutrophils. Blood 109: 4487-4493.
7. Hu, N., J. Westra, M. G. Huitema, M. Bijl, E. Brouwer, C. A. Stegeman, P. Heeringa, P. C. Limburg, and C. G. M. Kallenberg. 2009. Coexpression of CD177 and membrane proteinase 3 on neutrophils in antineutrophil cytoplasmic autoantibody-associated systemic vasculitis: anti-proteinase 3-mediated neutrophil activation is independent of the role of CD177-expressing neutrophils. Arthritis Rheum. 60: 1548-1557.
8. Abdel-Salam, B., C. Iking-Konert, M. Schneider, K. Andrassy, and G. M. Hänsch. 2004. Autoantibodies to neutrophil cytoplasmic antigens (ANCA) do not bind to polymorphonuclear neutrophils in blood. Kidney Int. 66: 1009-1017.
9. Finkielman, J. D., P. A. Merkel, D. Schroeder, G. S. Hoffman, R. Spiera, E.W. St Clair, J. C. Davis, Jr., W. J. McCune, A. K. Lears, S. R. Ytterberg, et al; WGET Research Group. 2007. Antiproteinase 3 antineutrophil cytoplasmic antibodies and disease activity in Wegener granulomatosis. Ann. Intern. Med. 147: 611-619.
10. Griffith, M. E., A. Coulthart, S. Pemberton, A. J. T. George, and C. D. Pusey. 2001. Anti-neutrophil cytoplasmic antibodies (ANCA) from patients with systemic vasculitis recognize restricted epitopes of proteinase 3 involving the catalytic site. Clin. Exp. Immunol. 123: 170-177.
11. Van Der Geld, Y. M., A. Simpelaar, R. Van Der Zee, J. W. Tervaert, C. A. Stegeman, P. C. Limburg, and C. G. Kallenberg. 2001. Antineutrophil cytoplasmic antibodies to proteinase 3 in Wegener's granulomatosis: epitope analysis using synthetic peptides. Kidney Int. 59: 147-159.
12. Williams, R. C., Jr., R. Staud, C. C. Malone, J. Payabyab, L. Byres, and D. Underwood. 1994. Epitopes on proteinase-3 recognized by antibodies from patients with Wegener's granulomatosis. J. Immunol. 152: 4722-4737.
13. Selga, D., M. Segelmark, J. Wieslander, L. Gunnarsson, and T. Hellmark. 2004. Epitope mapping of anti-PR3 antibodies using chimeric human/mouse PR3 recombinant proteins. Clin. Exp. Immunol. 135: 164-172.
14. Chang, L., S. Binos, and J. Savige. 1995. Epitope mapping of anti-proteinase 3 and anti-myeloperoxidase antibodies. Clin. Exp. Immunol. 102: 112-119.
15. Sommarin, Y., N. Rasmussen, and J. Wieslander. 1995. Characterization of monoclonal antibodies to proteinase-3 and application in the study of epitopes for classical anti-neutrophil cytoplasm antibodies. Exp. Nephrol. 3: 249-256.
16. Van Der Geld, Y. M., P. C. Limburg, and C. G. M. Kallenberg. 1999. Characterization of monoclonal antibodies to proteinase 3 (PR3) as candidate tools for epitope mapping of human anti-PR3 autoantibodies. Clin. Exp. Immunol. 118: 487-496.
17. Jenne, D. E., L. Fröhlich, A. M. Hummel, and U. Specks. 1997. Cloning and functional expression of the murine homologue of proteinase 3: implications for the design of murine models of vasculitis. FEBS Lett. 408: 187-190.
18. Höpfner, K. P., E. Kopetzki, G. B. Kresse, W. Bode, R. Huber, and R. A. Engh. 1998. New enzyme lineages by subdomain shuffling. Proc. Natl. Acad. Sci. USA 95: 9813-9818.
19. Sun, J., D. N. Fass, J. A. Hudson, M. A. Viss, J. Wieslander, H. A. Homburger, and U. Specks. 1998. Capture-ELISA based on recombinant PR3 is sensitive for PR3-ANCA testing and allows detection of PR3 and PR3-ANCA/PR3 immune-complexes. J. Immunol. Methods 211: 111-123.
20. Bories, D., M. C. Raynal, D. H. Solomon, Z. Darzynkiewicz, and Y. E. Cayre. 1989. Down-regulation of a serine protease, myeloblastin, causes growth arrest and differentiation of promyelocytic leukemia cells. Cell 59: 959-968.
21. Campanelli, D., M. Melchior, Y. Fu, M. Nakata, H. Shuman, C. Nathan, and J. E. Gabay. 1990. Cloning of cDNA for proteinase 3: a serine protease, antibiotic, and autoantigen from human neutrophils. J. Exp. Med. 172: 1709-1715.
22. Sturrock, A. B., R. Espinosa, III, J. R. Hoidal, and M. M. Le Beau. 1993. Localization of the gene encoding proteinase-3 (the Wegener's granulomatosis autoantigen) to human chromosome band 19p13.3. Cytogenet. Cell Genet. 64: 33-34.
23. Fujinaga, M., M. M. Chernaia, R. Halenbeck, K. Koths, and M. N. James. 1996. The crystal structure of PR3, a neutrophil serine proteinase antigen of Wegener's granulomatosis antibodies. J. Mol. Biol. 261: 267-278.
24. Korkmaz, B., S. Attucci, T. Moreau, E. Godat, L. Juliano, and F. Gauthier. 2004. Design and use of highly specific substrates of neutrophil elastase and proteinase 3. Am. J. Respir. Cell Mol. Biol. 30: 801-807.
25. Korkmaz, B., E. Hajjar, T. Kalupov, N. Reuter, M. Brillard-Bourdet, T. Moreau, L. Juliano, and F. Gauthier. 2007. Influence of charge distribution at the active site surface on the substrate specificity of human neutrophil protease 3 and elastase. A kinetic and molecular modeling analysis. J. Biol. Chem. 282: 1989-1997.
26. Korkmaz, B., T. Moreau, and F. Gauthier. 2008. Neutrophil elastase, proteinase 3 and cathepsin G: physicochemical properties, activity and physiopathological functions. Biochimie 90: 227-242. (Pubitemid 351187763)
27. Wiesner, O., R. D. Litwiller, A. M. Hummel, M. A. Viss, C. J. McDonald, D. E. Jenne, D. N. Fass, and U. Specks. 2005. Differences between human proteinase 3 and neutrophil elastase and their murine homologues are relevant for murine model experiments. FEBS Lett. 579: 5305-5312.
28. Korkmaz, B., S. Attucci, E. Hazouard, M. Ferrandiere, M. L. Jourdan, M. Brillard-Bourdet, L. Juliano, and F. Gauthier. 2002. Discriminating between the activities of human neutrophil elastase and proteinase 3 using serpin-derived fluorogenic substrates. J. Biol. Chem. 277: 39074-39081.
29. Rooney, C. P., C. Taggart, R. Coakley, N. G. McElvaney, and S. J. O'Neill. 2001. Anti-proteinase 3 antibody activation of neutrophils can be inhibited by α1- antitrypsin. Am. J. Respir. Cell Mol. Biol. 24: 747-754.
30. Dementiev, A., J. Dobó, and P. G. Gettins. 2006. Active site distortion is sufficient for proteinase inhibition by serpins: structure of the covalent complex of α1-proteinase inhibitor with porcine pancreatic elastase. J. Biol. Chem. 281: 3452-3457.
31. Sundberg, E. J., and R. A. Mariuzza. 2002. Molecular recognition in antibody-antigen complexes. Adv. Protein Chem. 61: 119-160.
32. Li, Y., H. Li, F. Yang, S. J. Smith-Gill, and R. A. Mariuzza. 2003. X-ray snapshots of the maturation of an antibody response to a protein antigen. Nat. Struct. Biol. 10: 482-488.
33. Korkmaz, B., A. Kuhl, B. Bayat, S. Santoso, and D. E. Jenne. 2008. A hydrophobic patch on proteinase 3, the target of autoantibodies in Wegener granulomatosis, mediates membrane binding via NB1 receptors. J. Biol. Chem. 283: 35976-35982.
34. Moreau, T., K. Baranger, S. Dadé, S. Dallet-Choisy, N. Guyot, and M. L. Zani. 2008. Multifaceted roles of human elafin and secretory leukocyte proteinase inhibitor (SLPI), two serine protease inhibitors of the chelonianin family. Biochimie 90: 284-295.
35. Tsunemi, M., Y. Matsuura, S. Sakakibara, and Y. Katsube. 1993. Crystallization of a complex between an elastase-specific inhibitor elafin and porcine pancreatic elastase. J. Mol. Biol. 232: 310-311.
36. Korkmaz, B., J. Jaillet, M. L. Jourdan, A. Gauthier, F. Gauthier, and S. Attucci. 2009. Catalytic activity and inhibition of wegener antigen proteinase 3 on the cell surface of human polymorphonuclear neutrophils. J. Biol. Chem. 284: 19896-19902.
37. 1-antitrypsin complexes in inflammatory fluids. FEBS Lett. 314: 117-121.
38. 1-antitrypsin complexation to disease activity in Wegener's granulomatosis. Clin. Exp. Immunol. 93: 405-410.
39. van der Geld, Y. M., A. T. Tool, J. Videler, M. de Haas, J. W. Tervaert, C. A. Stegeman, P. C. Limburg, C. G. Kallenberg, and D. Roos. 2002. Interference of PR3-ANCA with the enzymatic activity of PR3: differences in patients during active disease or remission of Wegener's granulomatosis. Clin. Exp. Immunol. 129: 562-570.
40. van de Wiel, B. A., K. M. Dolman, C. H. van der Meer-Gerritsen, C. E. Hack, A. E. von dem Borne, and R. Goldschmeding. 1992. Interference of Wegener's granulomatosis autoantibodies with neutrophil proteinase 3 activity. Clin. Exp. Immunol. 90: 409-414.
41. 1- antitrypsin PiZ allele carriers and non-carriers with Wegener's granulomatosis. Eur. J. Clin. Invest. 26: 786-792.
42. Chang, L., and J. Savige. 1993. Studies to demonstrate inhibition of functional activity of neutrophil lysosomal enzymes with ANCA. Adv. Exp. Med. Biol. 336: 97-100.
43. Daouk, G. H., R. Palsson, and M. A. Arnaout. 1995. Inhibition of proteinase 3 by ANCA and its correlation with disease activity in Wegener's granulomatosis. Kidney Int. 47: 1528-1536.
44. Elzouki, A. N., M. Segelmark, J. Wieslander, and S. Eriksson. 1994. Strong link between the alpha 1-antitrypsin PiZ allele and Wegener's granulomatosis. J. Intern. Med. 236: 543-548.